-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, C2ypTF//lgEfRK1UFL2v9tVBRmwuAVvngyEPh0pNcDvFGc0JHsjU9aT7xNiZ9DYe BzPFCiaD2JvopjSyAh8B6A== 0000950135-96-001785.txt : 19960425 0000950135-96-001785.hdr.sgml : 19960425 ACCESSION NUMBER: 0000950135-96-001785 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19960224 FILED AS OF DATE: 19960424 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENOME THERAPEUTICS CORP CENTRAL INDEX KEY: 0000356830 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 042297484 STATE OF INCORPORATION: MA FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-10824 FILM NUMBER: 96550003 BUSINESS ADDRESS: STREET 1: 1OO BEAVER ST CITY: WALTHAM STATE: MA ZIP: 02154 BUSINESS PHONE: 6178935007 MAIL ADDRESS: STREET 1: 100 BEAVER STREET CITY: WALTHAM STATE: MA ZIP: 02154 FORMER COMPANY: FORMER CONFORMED NAME: COLLABORATIVE RESEARCH INC DATE OF NAME CHANGE: 19920703 10-Q/A 1 GENOME THERAPEUTICS AMENDMENT #1 TO FORM 10-Q 1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ------------------- AMENDMENT NO. 1 TO FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For Quarter Ended: February 24, 1996 ----------------- Commission File No: 0-10824 ------- GENOME THERAPEUTICS CORPORATION ------------------------------- (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) MASSACHUSETTS 04-2297484 ------------- ---------- (STATE OR OTHER JURISDICTION (I.R.S. EMPLOYER IDENTIFICATION OF INCORPORATION OR ORGANIZATION) NO.) 100 BEAVER STREET; WALTHAM, MASSACHUSETTS 02154 - --- ------ ------ ------- ------------- ----- (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE) REGISTRANT'S TELEPHONE NUMBER: (617) 893-5007 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No --- --- Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date. COMMON STOCK 16,899,090 - ------ ----- ------------------------- $.10 PAR VALUE Outstanding April 8, 1996 ---- --- ----- SERIES B RESTRICTED STOCK 57,512 - ------ - ---------- ----- ------------------------- $.10 PAR VALUE Outstanding April 8, 1996 ---- --- ----- 2 This amendment reflects the incorporation of Insert A - Tabulation of Matters Voted on by Security Holders into Part II, Item 4 of Form 10Q for period ended February 24, 1996. 3 INSERT A The company's Special Meeting in lieu of an Annual Meeting was held on February 16, 1996. At the meeting, shareholders took the following actions: 1) Election of Directors
Name of Nominee Shares Voting --------------- ------------- FOR WITHHOLD AUTHORITY Robert J. Hennessey 11,483,593 27,142 Orrie M. Friedman 11,473,673 37,062 Philip J. Leder 11,488,093 22,642 Lawrence Levy 11,479,043 31,692 Donald J. McCarren 11,478,893 34,842 Steven M. Rauscher 11,476,093 34,642
2) To approve 1995 Stock Option Plan FOR AGAINST ABSTAIN NO VOTING 6,922,764 718,771 77,508 3,791,692 3) To approve a grant of stock option to Robert J. Hennessey FOR AGAINST ABSTAIN NO VOTING 4,927,609 2,957,466 75,508 3,550,152 4) To approve a grant of stock option to Dr. Philip Leder FOR AGAINST ABSTAIN NO VOTING 7,419,276 467,599 73,708 3,550,152 5) To approve a grant of stock option to Lawrence Levy FOR AGAINST ABSTAIN NO VOTING 7,403,391 480,784 76,408 3,550,152
4
6) To approve a grant of stock option to Donald J. McCarren FOR AGAINST ABSTAIN NO VOTING 7,407,566 478,009 75,008 3,550,152 7) To approve a grant of stock option to Steven M. Rauscher FOR AGAINST ABSTAIN NO VOTING 7,407,164 476,934 76,485 3,550,152 8) To ratify the selection of Arthur Andersen LLP as the company's auditors for the fiscal year ending August 31, 1996. FOR AGAINST ABSTAIN NO VOTING 11,434,608 42,787 33,340 0
5 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned thereunto duly authorized who also serves in the capacity of principal financial officer. Genome Therapeutics Corporation /s/ Fenel M. Eloi ---------------------- Fenel M. Eloi (Principal Financial Officer) Date: April 22, 1996 -----END PRIVACY-ENHANCED MESSAGE-----